Timo Siitonen - Canc Ctr, Oulu Univ Hosp

基本信息

Career Trajectory

Bio

No content for now

Research Interests

Papers共 42 篇Author StatisticsCo-AuthorSimilar Experts

By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选

Bexmarilimab Plus Azacitidine for High-Risk Myelodysplastic Syndrome and Relapsed or Refractory Acute Myeloid Leukaemia: Results from the Dose-Escalation Part of a Multicentre, Single-Arm, Phase 1/2 Trial

Mika Kontro, Anthony Selwyn Stein, Marja Pyörälä,Johanna Rimpiläinen,Timo Siitonen, Arno Ylitalo,Marie-Louise Fjällskog,Juho Jalkanen, Sofia Aakko, Inka Pawlitzky,Maija Hollmén,Naval Daver

The Lancet Haematology (2025)

Cited0Views0WOSBibtex

Capillary Sampling Enables Venetoclax Concentration Measurement in Acute Myeloid Leukaemia Within Academic Multicentre Trial

Sari Kytölä, Mika Kurkela, Johanna I Kiiski, Ida Vänttinen, Tanja Ruokoranta, Anu Partanen, Annasofia Holopainen, Marja Pyörälä, Milla E L Kuusisto,Timo Siitonen, Sirpa Koskela,Johanna Rimpiläinen, Pia Ettala,Heikki Kuusanmäki,Mikko Niemi, Janne T Backman,Mika Kontro

Basic & clinical pharmacology & toxicologyno. 6 (2025): e70041-e70041

Cited0Views0WOSBibtex

Integrating Computational Cytomorphological Analysis of Bone Marrow Smears and Clinical Data for Predicting Response to Venetoclax and Hypomethylating Agents in AML

Henri Sundquist, Mikael Tatun, Mikko Purhonen, Laura Toivanen,Johanna Rimpiläinen,Samuli Rounioja,Timo Siitonen,Marja Pyörälä,Pentti Mäntymaa,Sari Kytölä,Kimmo Porkka,Sanna Siitonen,Heikki Kuusanmäki,Mika Kontro,Oscar E. Brück

Bloodno. Supplement 1 (2024): 4320-4320

Cited0Views0Bibtex

Encouraging Efficacy of Bexmarilimab with Azacitidine in Relapsed or Refractory MDS in Bexmab Ph1/2 Study

Mika Kontro, Anthony S. Stein,Marja Pyörälä,Johanna Rimpiläinen,Timo Siitonen,Jenna H Rannikko, Jesper Mickos,Rita Turpin, Milja Hakoniemi, Birge Berns,Sofia Aakko,Inka Pawlitzky,Maija Hollmén,Amer M. Zeidan,Naval Daver

Blood（2024）

Cited0Views0Bibtex

Integrative Analysis of Transcriptomic and Proteomic Data Identifies Patterns of Primary Resistance to Venetoclax-Azacitidine and Reveals Targetable Vulnerabilities in Acute Myeloid Leukemia (AML)

Ida Vänttinen,Joseph Saad,Tanja Ruokoranta,Sari Kytölä, Pia-Sofia Ettala,Marja Pyörälä,Johanna Rimpiläinen,Timo Siitonen,Caroline A. Heckman,Heikki Kuusanmäki,Mika Kontro

Bloodno. Supplement 1 (2024): 2757-2757

Cited0Views0Bibtex

Targeting Venetoclax Resistance in TP53-Mutated Acute Myeloid Leukemia

Ida Vanttinen,Tanja Ruokoranta,Joseph J. Saad,Sari Kytola,Monica Hellesoy,Stein-Erik Gullaksen, Pia-Sofia Ettala,Marja Pyorala,Johanna Rimpilainen,Timo Siitonen,Krister Wennerberg,Bjorn T. Gjertsen,Caroline A. Heckman,Mika Kontro,Heikki Kuusanmaki

BLOOD（2023）

Cited0Views0Bibtex

Impact of the Number of Cryopreserved CD34+ Cells in the Infused Blood Grafts on Hematologic Recovery and Survival in Myeloma Patients after Autologous Stem Cell Transplantation: Experience from the GOA Study

Anu Partanen,Antti Turunen,Raija Silvennoinen,Jaakko Valtola,Marja Pyorala,Timo Siitonen,Anu Sikio,Mervi Putkonen,Marja Sankelo,Karri Penttila,Taru Kuittinen,Pentti Mantymaa,Jukka Pelkonen,Esa Jantunen,Ville Varmavuo

JOURNAL OF CLINICAL APHERESIS（2023）

Cited4Views0WOSBibtex

Encouraging Efficacy Observed in Bexmab Study: A Phase 1/2 Study to Assess Safety and Efficacy of Bexmarilimab in Combination with Standard of Care in Myeloid Malignancies

Mika Kontro,Anthony Selwyn Stein,Marja Pyorala,Johanna Rimpilainen,Timo Siitonen,Maija Hollmen,Marie-Louise Fjaellskog,Inka Pawlitzky,Amer M. Zeidan,Naval Daver

BLOOD (2023)

Cited0Views0Bibtex

Author Statistics

Co-Author

Co-Institution

D-Core

合作者
学生
导师

No result temporarily, you can search similar Scholar with the same research interest

Data Disclaimer

The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn